Pulse Biosciences surges 80% on FDA approval for atrial fibrillation study
Regulatory milestone for nanosecond pulsed field ablation technology drives stock to near 52-week high despite earnings miss
Pulse Biosciences shares have surged approximately 80% since mid-January, climbing to near the company's 52-week high after receiving FDA approval to initiate a pivotal clinical study for its atrial fibrillation treatment technology.
The Hayward, California-based bioelectrical medicine company's stock, which was trading around $13.93 in mid-January, reached $25.08 on Wednesday—just shy of its 52-week high of $26.30. The rally comes despite the company reporting fourth-quarter earnings that missed revenue expectations.
The primary catalyst driving the gains came in December, when the FDA granted approval for an Investigational Device Exemption, allowing Pulse Biosciences to commence its NANOPULSE-AF clinical study. The trial will evaluate the company's nPulse Cardiac Catheter System for treating paroxysmal atrial fibrillation, a heart rhythm disorder affecting millions of Americans.
According to MedTech Dive, the regulatory clearance represents a significant milestone for Pulse's nanosecond pulsed field ablation (nsPFA) technology, which uses ultra-short electrical pulses to treat cardiac tissue without thermal damage—a potential advantage over existing ablation methods.
Clinical results from earlier studies showed promise, with data indicating 100% procedural success at six months and 96% success at one year. The NANOPULSE-AF trial will be the first U.S.-based pivotal study to evaluate nsPFA technology for atrial fibrillation treatment.
In its fourth-quarter earnings report, Pulse Biosciences reported adjusted earnings per share of -$0.26, beating analyst estimates of -$0.31 by 16.1%. However, revenue of $0.3 million missed the $0.5 million consensus by 47%, reflecting the company's pre-revenue stage as it advances clinical programs.
Analysts maintain a positive outlook on the stock, with two Buy ratings and no Hold or Sell recommendations. The average price target of $22.00 suggests some caution about the recent rally, though shares are currently trading above this level.
Pulse Biosciences ended the quarter with a cash runway estimated at five to six quarters at current burn rates, providing sufficient capital to execute the NANOPULSE-AF trial through its initial phases. The company's high beta of 1.785 reflects its volatility typical of development-stage biotech companies.
The FDA approval marks a shift in strategy for Pulse Biosciences, which previously received Breakthrough Device Designation in July 2024 for its CellFX nsPFA Cardiac Surgery System. That designation came after the FDA requested human clinical data, prompting the company to pursue the premarket approval pathway rather than the earlier 510(k) clearance route.
Atrialial fibrillation represents a significant market opportunity, affecting an estimated 6 million Americans and costing the healthcare system billions annually. Current treatment options include medication and thermal ablation procedures, which can damage surrounding tissue. Non-thermal nsPFA technology could offer a safer alternative if clinical trials demonstrate efficacy comparable to existing approaches.
The company's heavy insider ownership of 73.9% suggests management confidence in the technology's potential, though institutional ownership remains relatively low at 8.7%. The stock's price-to-book ratio of 16.82 reflects investor expectations for future growth rather than current financial performance.
With the IDE approval secured, investors will be focused on trial enrollment timelines and initial safety data from the NANOPULSE-AF study. The next significant catalyst could come from interim results, which if positive, could support further gains as the company advances toward potential regulatory submission.